
Gain Therapeutics, Inc.: financial statements
Price
$1.00
November 20, 2026Market cap $44M
What Ploutos Investor adds for Gain Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
| Line | 2023 | 2024 | 2025 | Average a year |
|---|---|---|---|---|
| Revenue | $55.2K | – | – | |
| Operating income | -$22M | -$20M | -$19M | |
| Net income | -$22M | -$20M | -$20M | |
| Earnings per share | -$1.71 | -$0.89 | -$0.61 | |
| Earnings per share, basic | -$1.71 | -$0.89 | -$0.61 | |
| Margins | ||||
| Operating margin | -40,328.3% | – | – | |
| Net margin | -40,354.3% | – | – | |
Financial statements
GANX's revenue, profits and cash flows from 2020 to 2022, 3 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
Leases
Dec 31, 2025Operating leases
$331.1K
Finance leases
–
- Average discount rate
- 3.8%
- Lease cost for the year
- $177.9K
The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing
Lease liability by year
Leases
GANX's leases from 2021 to 2022, 2 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Pension plans
Dec 31, 2025Defined-benefit pensions
75%funded
Deficit $390.5K.
The obligation is the present value of the pensions employees have already earned, at December 31, 2025. A deficit is the company's to fill with contributions. The filing
Pensions funded, by year
Pensions funded, by year
How far GANX's pension plans were funded, from 2021 to 2022, 2 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
From the statutory to the effective tax rate, 2025
Dec 31, 2025Statutory rate
21.0%
Effective rate
-4.5%
The company paid -4.5% in tax on its profit, 25.5 points below the US federal rate (21.0%). Below, the reasons it gives.
Statutory rate
21.0%
Prior-year adjustments
+17.9 pts
Foreign rate differential · Switzerland
+1.2 pts
Non-taxable income · Australia
+1.2 pts
Change in valuation allowance
-37.4 pts
GILTI
-3.7 pts
Non-deductible expenses · Australia
-2.8 pts
Non-deductible expenses
-1.0 pts
Not itemized in the filing
-0.1 pts
Smaller lines (3)
-0.8 pts
Effective rate
-4.5%
One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing
Effective tax rate by year
In a year of a loss or of very small profits the rate comes out negative or very large and says little. Those years are in grey.
Effective tax rate by year
The tax rate GANX paid on its profit, from 2020 to 2022, 3 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Claims ahead of shareholders
What stands between the business and its shareholders besides the debt, and the financial assets on the other side, from the latest balance sheet.
Besides its $676.7K of debt, $308.5K of other claims rank ahead of the shares, about 0.7% of the market value.
Ahead of the shares
- at Dec 31, 2025; $390.5K before tax, after tax at 21%
- $308.5K
From the balance sheet of September 30, 2026. The retirement and environmental lines and the pension deficit come from the latest annual report when the quarter's filing does not state them, each with its own date. Market value at the price of November 20, 2026. A line is listed when it is at least 0.5% of the market value. A description of the balance sheet, not a valuation.
The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.
The full analysis
What do Gain Therapeutics's filings show?
These are Gain Therapeutics's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much debt does GANX have?
On December 31, 2025 Gain Therapeutics had total assets of $23M, debt of $401.0K and shareholders' equity of $19M.
Where are the figures from?
From Gain Therapeutics, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.